Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

31.6K
Overview
31.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation of Rhizoma Paridis saponins as novel entry inhibitors of Crimean-Congo hemorrhagic fever virus.

Cell insight·2026
Same author

Differential inhibition of Morbillivirus and Henipavirus polymerases by ERDRP-0519 and structure-guided inhibitor optimization.

Cell·2026
Same author

Selective capture and digital counting of intact HIV pseudovirus using designer DNA nets, tethered motion, and photonic resonator interferometric scattering microscopy.

APL bioengineering·2026
Same author

Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design to <i>In Vivo</i> Antiviral Efficacy.

Journal of medicinal chemistry·2026
Same author

Challenges and progress toward real-time detection of airborne viral pathogens.

Critical reviews in biotechnology·2026
Same author

Sangbaipi Decoction mitigates influenza pneumonia in mice by inhibiting ZBP1-mediated PANoptosis.

Journal of ethnopharmacology·2026

Related Experiment Video

Updated: Sep 27, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.5K

Ebola Virus Entry Inhibitors.

Ruikun Du1, Qinghua Cui1, Michael Caffrey2

  • 1Shandong University of Traditional Chinese Medicine, Jinan, China.

Advances in Experimental Medicine and Biology
|April 12, 2022
PubMed
Summary
This summary is machine-generated.

Ebola virus (EBOV) entry inhibitors are crucial for combating hemorrhagic fever. Research explores diverse therapeutic strategies beyond approved monoclonal antibodies (mAbs) to address resistance and emerging threats.

Keywords:
Drug repurposingEbola virusEntry inhibitorSmall moleculeTherapeutic mAb

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.2K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.4K

Related Experiment Videos

Last Updated: Sep 27, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.5K
Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.2K
Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

30.4K

Area of Science:

  • Virology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Ebola virus (EBOV) causes severe hemorrhagic fever epidemics in Africa.
  • Approved monoclonal antibody (mAb) drugs exist, but new threats necessitate further therapeutic development.

Purpose of the Study:

  • To review the EBOV entry process.
  • To summarize advancements in discovering and developing EBOV entry inhibitors.

Main Methods:

  • Review of current scientific literature on EBOV entry mechanisms.
  • Analysis of various therapeutic strategies and chemical structures targeting EBOV entry.

Main Results:

  • Detailed understanding of the EBOV cellular entry pathway.
  • Overview of diverse inhibitor classes: therapeutic antibodies, peptides, small molecules, and natural products.

Conclusions:

  • Continued research into novel EBOV entry inhibitors is vital.
  • Development of inhibitors is essential to counter potential resistance and related viruses.